Company intelligence / Profile preview
PLEURAN
Bratislava, Slovakiapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
PLEURAN produces Imunoglukan P4H®, a commercialized supplement based on beta-glucan (pleuran), shown in published studies to reduce the incidence of upper respiratory tract infections and support immune function, particularly in children and athletes undergoing physical stress. Continued clinical research is ongoing in immune modulation and infection prevention.
- Therapeutic areas
- Infectious DiseasesOncologyImmunology
- Modalities
- BiologicBeta-glucanNutritional supplement
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Collaborations with academic and scientific centers (unspecified, both domestic and international)
Beyond the preview
Go deeper on PLEURAN.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLEURAN.